Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate

BACKGROUND: Clinical trials have shown combinations of anti–tumor necrosis factor biologicals plus methotrexate (MTX) are more effective treatments for rheumatoid arthritis than biological monotherapies, based, in part, on the assumption that MTX reduces the immunogenicity of biologicals. However, c...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Mahony, Alison, John, Markus R., Cho, Hannah, Hashizume, Misato, Choy, Ernest H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992722/
https://www.ncbi.nlm.nih.gov/pubmed/29879987
http://dx.doi.org/10.1186/s12967-018-1532-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992722/
https://www.ncbi.nlm.nih.gov/pubmed/29879987
http://dx.doi.org/10.1186/s12967-018-1532-5

Ejemplares similares